Evidence map›Paper›PMID 35013377›Full record

Trial reportScientific reports2022

Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial.

Aleksandar Radosevic, Rita Quesada, Clara Serlavos, Juan Sánchez, Ander Zugazaga, Ana Sierra, Susana Coll, Marcos Busto, Guadalupe Aguilar, Daniel Flores and 12 more

Abstract readClinical Trial, Phase IIComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Microwave coagulation for liver metastases.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Aleksandar Radosevic *Department of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain. aradosevic@psmar.cat.
Rita Quesada *Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Clara SerlavosDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Juan SánchezDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Ander ZugazagaDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Ana SierraDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Susana CollHepatology Section, Gastroenterology Department, Hospital del Mar. IMIM, Barcelona, Spain.
Marcos BustoDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Guadalupe AguilarDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Daniel FloresDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Javier ArceDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
José María MaiquesDepartment of Radiology, Hospital del Mar de Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
Montserrat Garcia-RetortilloHepatology Section, Gastroenterology Department, Hospital del Mar. IMIM, Barcelona, Spain.
José Antonio CarrionHepatology Section, Gastroenterology Department, Hospital del Mar. IMIM, Barcelona, Spain.
Laura VisaDepartment of Oncology-IMIM-Ciberonc, Hospital del Mar, Barcelona, Spain.
María VillamonteDepartment of Surgery, Hospital del Mar, Barcelona, Spain.
Eva PueyoDepartment of Surgery, Hospital del Mar, Barcelona, Spain.
Enrique BerjanoBioMIT, Department of Electronic Engineering, Universitat Politècnica de València, Valencia, Spain.
Macarena TrujilloBioMIT, Department of Applied Mathematics, Universitat Politècnica de València, Valencia, Spain.
Patricia Sánchez-VelázquezDepartment of Surgery, Hospital del Mar, Barcelona, Spain.
Luís GrandeDepartment of Surgery, Hospital del Mar, Barcelona, Spain.
Fernando BurdioDepartment of Surgery, Hospital del Mar, Barcelona, Spain.

Funding

Spanish Government FIS - PI12/00799Spanish Ministerio de Ciencia, Innovación y Universidades under "Programa Estatal de I+D+i Orientada a los Retos de la Sociedad" RTI2018-094357-B-C21
6 · The paper itself

Abstract

Microwave (MWA) and radiofrequency ablation (RFA) are main ablative techniques for hepatocellular carcinoma (HCC) and colorectal liver metastasis (MT). This randomized phase 2 clinical trial compares the effectiveness of MWA and RFA as well as morphology of corresponding ablation zones. HCC and MT patients with 1.5-4 cm tumors, suitable for ablation, were randomized into MWA or RFA Groups. The primary endpoint was short-to-long diameter ratio of ablation zone (SLR). Primary technical success (TS) and a cumulative local tumor progression (LTP) after a median 2-year follow-up were compared. Between June 2015 and April 2020, 82 patients were randomly assigned (41 patients per group). For the per-protocol analysis, five patients were excluded. MWA created larger ablation zones than RFA (p = 0.036) although without differences in SLR (0.5 for both groups, p = 0.229). The TS was achieved in 98% (46/47) and 90% (45/50) (p = 0.108), and LTP was observed in 21% (10/47) vs. 12% (6/50) (OR 1.9 [95% CI 0.66-5.3], p = 0.238) of tumors in MWA vs. RFA Group, respectively. Major complications were found in 5 cases (11%) vs. 2 cases (4%), without statistical significance. MWA and RFA show similar SLR, effectiveness and safety in liver tumors between 1.5 and 4 cm.

Indexed as

Radiofrequency AblationAgedAged, 80 and overCarcinoma, HepatocellularColorectal NeoplasmsFemaleHumansLiver NeoplasmsMaleMicrowavesMiddle AgedProspective StudiesSingle-Blind MethodSpainTime FactorsTreatment Outcome

Identifiers

PMID35013377
PMCPMC8748896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.